Head-to-Head battle: new drug challenges standard for deadly lung disease
Disease control
Not yet recruiting
This study aims to see if a new drug called LYT-100 (deupirfenidone) works better and is as safe as the current standard drug, pirfenidone, for adults with idiopathic pulmonary fibrosis (IPF), a serious lung-scarring disease. About 1,100 participants will be randomly assigned to …
Phase: PHASE3 • Sponsor: PureTech • Aim: Disease control
Last updated Mar 03, 2026 14:07 UTC